keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Alamandine TFA 是肾素-血管紧张素系统 (RAS) 的成员,是一种血管活性肽,是 G 蛋白偶联受体 MrgD 的内源性配体。它通过抗高血压作用来保护肾脏和心脏。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 369 | 现货 | ||
2 mg | ¥ 528 | 现货 | ||
5 mg | ¥ 756 | 现货 | ||
10 mg | ¥ 1,190 | 现货 | ||
25 mg | ¥ 2,370 | 现货 | ||
50 mg | ¥ 3,560 | 现货 | ||
100 mg | ¥ 5,150 | 现货 | ||
500 mg | ¥ 10,800 | 现货 |
产品描述 | Alamandine TFA , a member of the renin-angiotensin system (RAS), a vasoactive peptide, is an endogenous ligand of the G protein-coupled receptor MrgD. Alamandine TFA targets to protect the kidney and heart through anti-hypertensive actions[1][2]. |
体外活性 | Alamandine TFA is generated by catalysis of Ang A via ACE2 or directly from Angiotensin 1-7 (Ang-(1-7)). Derived from angiotensin II (Ang II) by Ang II-converting enzyme 2 (ACE2), it shows vasodilating (thus protective) properties. Ang (1-7) can be decarboxylated to a peptide called Alamandine TFA. Alamandine TFA is also an endogenous peptide identified in human blood[1]. Alamandine TFA elevates cAMP concentration in primary endothelial and mesangial cells, also suggesting Gs coupling[2]. Alamandine TFA decreases secretion, expression, and blood levels of leptin. Alamandine TFA induced expression of iNOS and plasminogen activator inhibitor-1 (PAI-1) in adipose tissue and isolated adipocytes[2]. |
体内活性 | Alamandine TFA (0.15 ?μL/h; administered by mini-osmotic pumps; for 6 weeks) treatment ameliorates hypertension and impaires left ventricle (LV) function in SHRs. Also decreases the mass gains of heart and lung in SHRs, suppresses cardiomyocyte cross-sectional area expansion, and inhibits the mRNA levels of atrial natriuretic peptide and brain natriuretic peptide[3]. heart and lung in SHRs, suppresses cardiomyocyte cross-sectional area expansion, and inhibits the mRNA levels of atrial natriuretic peptide and brain natriuretic peptide[3]. |
分子量 | 969.02 |
分子式 | C42H63F3N12O11 |
CAS No. | T37496L |
keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Alamandine TFA T37496L Endocrinology/Hormones RAAS Inhibitor inhibitor inhibit